Analytical and Chemical Enhancements to Improve Efficacy and Accuracy of Therapeutic Oligonucleotides
See how top pharma players are addressing impure, unstable, and off-target oligos
Boosting the Efficacy of Safe, Scalable, & Precise Vaccines
Innovations in mRNA Technology, RNA Therapeutics, and Cancer Immunotherapy for 2024
.png)
Tumbler: A Highly Customizable Antibody Optimization Suite
On-demand presentation, presented by Michali Izhaky, Bioinformatics Scientist at Charles River
Leading Innovations in Fab, ScFv, & VHH Production and Engineering
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Advancing Immunotherapy: The Critical Role of GMP-Grade Cytokines in Cell Therapy
On-demand webinar presented by Ritwika Biswas, Field Application Scientist at Sino Biological
Optimizing Bispecific Antibody Production: From Identifying Optimal Pairings to Scale-up Processes
On-demand webinar presented by Dr Jiansheng Wu, Head of Protein Sciences and Vice President at WuXi Biologics
Unlocking the Future of Immune Cancer Therapy
A concise report featuring insights from the prominent though leaders of Immuno 2024.
MIT Team Create AI-Generated Universal COVID Vaccine
New COVID variants are still a significant risk; but could an AI-generated universal COVID vaccine be the key to overcoming this?
Gene Therapy Development
CGT Manufacturing: Key Considerations for Implementing AI/ML Approaches
AI/ML approaches are not some miracle ‘one size fits all' fix-all for delays and holdups in CGT manufacture, but the proper implementation of deep learning approaches and data interpretation may help speed up development.
Biomarkers & Precision Medicine
Improving Patient Response Through Effective Biomarker Development
Oxford Global's panel discussion brings together expert scientists in the field of immunology and biomarker development.
Regulation and Policy Interview with Scott Burger, Principal of Advanced Cell and Gene Therapy
Scott Burger, Principal of Advanced Cell and Gene Therapy, discusses some of the recent trends in regulation and policy surrounding cell and gene therapy development.
Drug Discovery & Development
Targeting oxMIF To Develop Novel Biotherapeutics
An interview with Michael Thiele, Chief Scientific Officer, OncoOne Research & Development GmbH.
Antibody & Protein Engineering
How AI is Changing the Game for Protein Design
Researchers at the University of Washington have succeeded in using machine learning to synthesise artificial enzymes which are actually functional in cells.
Manufacturing & Bioprocessing
AI in Gene Therapy: How Could Machine Learning Approaches Reshape Therapeutic Development?
As more developers bring their cell and gene therapy products to industry regulators, the need to drive cost and process efficiencies is on track to keep growing. Across the board, AI and machine learning approaches have the potential to streamline many aspects of development.
Drug Discovery & Development
Chipscreen Licences Eucure Biopharma's Keytruda Competitor for Greater China
The investigational bispecific antibody has demonstrated favourable efficacy and safety in preclinical in vivo testing.
CHO Cells and Engineering Cell Line Approaches: Addressing Challenges in Manufacturing
Regulatory approval is, as ever, a crucial factor to bear in mind during the later phases of clinical trials. Regardless of the cell line approach chosen, keeping a consistent process and product output is key for establishing a successful project without it being hamstrung at the final hurdle.
Manufacturing & Bioprocessing
Industry Insights Into the FDA's Plans for Revised Gene Therapy Approval Approaches
Some additional measures announced include the launch of the Cell and Gene Therapy Access Model, as well as the interpolation of RWE into trials and a potential move away from animal models in validating treatment efficacy.
Immuno-Oncology
Sensei Bio Presents Preclinical Data for Novel Antibody Therapeutic for Solid Tumours
Immuno-oncology company Sensei Bio gave a presentation which outlined convincing preclinical data for their novel antibody therapeutic.
Gene Therapy Development
FDA Pursues Accelerated Approval Path Following Cell and Gene Therapy Backlog
The announcement comes with the news that the cell and gene therapy manufacturing market is now worth US$ 19.3 billion, with a compound annual growth rate (CAGR) of 29% between 2022 and 2023.